Sort
51,593 grants matching “hepatitis”
Phase I Trials of Anti-Cancer Agents
$739,271Michael R Grever · Ohio State University · U01 · FY2011 · CA
Research Project 1 - Hepatocellular Genetic Epidemiology of Fatty Liver Disease in Hispanics
$739,200Joanne E Curran · University Of Texas Rio Grande Valley · U54 · FY2023 · HG
Natural model for evaluating within- and cross-species virus transmission
$739,159Ryan Langlois · University Of Minnesota · R01 · FY2023 · AI
Computation and Repurposing to identfy antivirals directed against dominant
$739,116Vijay S Pande · Stanford University · U19 · FY2015 · AI
Evaluation of a persuasive health communication intervention designed to increase HIV/HCV screening among emergency departments patients who currently, formerly or never injected drugs
$739,067Roland C Merchant · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · DA
Immune response to COVID-19 vaccine in HIV infected men and women
$739,018Charles R Rinaldo · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AI
Mindful Body Awareness Training as an Adjunct to Medication Assisted Treatment for Opioid Use Disorder
$738,950Cynthia J Price · University Of Washington · R33 · FY2020 · AT
Clinical Research Resources and Facilities
$738,872Judith E Feinberg · West Virginia University · U54 · FY2021 · GM
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
$738,773Lynn Elizabeth Fiellin · Yale University · R01 · FY2011 · AA
Adenovirus Protease Regulation and Antiviral Development
$738,742Brookhaven Science Assoc-Brookhaven Lab · R01 · FY2004 · AI
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology
$738,557Charles M. Rice · Rockefeller University · R01 · FY2025 · AI
Novel Pathways for Kidney Stone Formation
$738,557Eric N Taylor · Brigham And Women'S Hospital · R01 · FY2020 · DK
HBV-specific T cell immunity in HBV/HIV coinfection
$738,419Michael Jeffrey Vinikoor · University Of Alabama At Birmingham · R37 · FY2023 · AI
RACIAL DIFFERENCE IN HCV/HOST INTERACTIONS
$738,193University Of Tennessee Health Sci Ctr · U19 · FY2001 · AI
Genetic Modifiers of Iron Status in Hemochromatosis HFE C282Y Homozygotes
$738,146Christine E McLaren · University Of California-Irvine · R24 · FY2016 · DK
Clinical Trial of Short Course vs. INH for LTBI in Jail
$738,122University Of California San Francisco · U01 · FY2004 · AI
Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention
$738,109Carey Farquhar · University Of Washington · R01 · FY2021 · DA
Characterization of Genomics and Metabolomics among Individuals Highly-Exposed, but resistant to Mtb Infection
$738,076Neel Rajnikant Gandhi · Emory University · R01 · FY2020 · AI
Fatty liver disease and its determinants in an American Indian Population: the Strong Heart Study
$737,991Shelley A Cole · Texas Biomedical Research Institute · R01 · FY2018 · DK
Genetic disorders of immunodeficiency and inflammatory disease
$737,955Eric Hanson · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2018 · AR
BioLINCC
$737,718Carol Giffen · Information Management Services, Inc. · N01 · FY2009 · HL
Indiana University Center for Pediatric Pharmacology
$737,674Jamie L Renbarger · Indiana University Indianapolis · U54 · FY2014 · HD
Innate Immune Control of West Nile Virus
$737,600Michael J Gale · University Of Washington · R01 · FY2014 · AI
Adoptive MHC-E-Restricted T Cell Therapy for the Treatment of Chronic Hepatitis B Virus Infection
$737,535Benjamin J Burwitz · Oregon Health & Science University · R01 · FY2021 · AI
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
$737,531Michael Karin · University Of California, San Diego · U01 · FY2018 · AA